Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and immunogenicity follow-up of HEPLISAV versus Engerix-B in adults with chronic kidney disease previously vaccinated against hepatitis B
2010-022372-31Phase 3Completed
- Sponsor
- Dynavax Technologies
- Start
- Feb 2011
- Modality
- Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of Heplisav-B and Hepatitis B vaccine in hepatitis B (HBV) (2 arms), sponsored by Dynavax Technologies. Primary endpoint: Seroprotection rate. Started Feb 2011; status: completed.
02
Drugs
Heplisav-BHepatitis B vaccine
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on 2010-022372-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022372-31.